This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

A Buysider's Preview of Biotech's Biggest Conference

Nate Sadeghi breaks down next week's J.P. Morgan Healthcare Conference.

Breaking Up With Gilead Sciences
Breaking Up With Gilead Sciences

12/17/12 - 07:00 AM EST

Gilead is a great company and stock, but expectations are high and outperformance in 2013 will be tough.

Time For Common Sense Gun Control Has Arrived

The tragedy in Newtown should bring gun owners and opponents together.

Sarepta Is Still A Buy: Recent Concerns Much Ado About Nothing

Eteplirsen is a blockbuster drug for DMD, a view bolstered by Friday's 62-week data.

Thoughts on Bio-Pharma Investor Sentiment Going Into 2013

Medical innovation is increasing but ever-escalating drug prices aren't sustainable.

Nate Sadeghi's 2012 Biotech Stock Report Card

TheStreet columnist takes a look back at his best and worst biotech stock calls in 2012.

Seattle Genetics: A Short Thesis That's Been Right And Wrong

Sales of the cancer drug Adcetris have fallen short but Seattle Genetics' stock price climbs higher.

Arena Pharma Is Still A Good Short
Arena Pharma Is Still A Good Short

11/05/12 - 07:00 AM EST

A marginal effective weight-loss pill sold into an overhyped market by a mediocre partner makes Arena a short.

Achillion Pharma Worthy of New Look
Achillion Pharma Worthy of New Look

10/31/12 - 08:16 AM EDT

The winnowing of competing hepatitis C drugs has made Achillion's pipeline more compelling.

United Therapeutics Could Lose The Battle For PAH Therapies

An FDA decision expected this week could easily go against United Therapeutics.

Page 1 of 5
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs